Tavotek Biotherapeutics Closes $35M Series B Financing


Tavotek Biotherapeutics, a Lower Gwynedd PA-based biotech company, raised $35M in Series B funding.

The round was led by CS Capital with participation from Fontus Capital.

The company intends to use the funds to accelerate:

  • the Phase 1 clinical development of several antibody drugs to start in early 2022,
  • the CMC and IND development of multiple other oncology pipelines, and
  • the development of its multicyclic intracellular peptide (MIP) programs.

Tavotek Biotherapeutics is advancing medicines for patients suffering from debilitating diseases with significant unmet medical needs. The company has a pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases. Its research platforms are built upon three breakthrough technologies: 

  • TavoSelect (an innovative Phage Display Library that generates conformational selective human full-length and single domain antibodies); 
  • TavoPrecise (a differentiated engineering platform for next generation tissue-specific biologics); and 
  • TavoMIP (a multicyclic peptide platform that makes undruggable targets more accessible). 

Tavotek has two R&D centers: one in Lower Gwynedd, Pennsylvania and another in Suzhou, China.